{{distinguish|clonazepam|clobazam|cinolazepam}}
{{Drugbox
| Watchedfields = changed
| verifiedrevid = 447550704
| IUPAC_name = 7-chloro-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl N,N-dimethylcarbamate
| image = Camazepam.svg
| width = 222
| image2 = Camazepam3d.png
| width2 = 180

<!--Clinical data-->
| tradename =  
| pregnancy_category = ?
| legal_CA = Schedule IV
| legal_DE = Anlage III
| legal_UK = Class C
| legal_US = Schedule IV
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability = 90%
| metabolism = [[Liver|Hepatic]]
| elimination_half-life = 6,4-10,5 hours
| excretion = [[Kidney|Renal]]

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 36104-80-0
| ATC_prefix = N05
| ATC_suffix = BA15
| PubChem = 37367
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01489
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 34285
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = HZ3XRH03C3
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07315
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1095282

<!--Chemical data-->
| C=19 | H=18 | Cl=1 | N=3 | O=3 
| molecular_weight = 371.8
| smiles = ClC1=CC2=C(C=C1)N(C)C(C(N=C2C3=CC=CC=C3)OC(N(C)C)=O)=O
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C19H18ClN3O3/c1-22(2)19(25)26-17-18(24)23(3)15-10-9-13(20)11-14(15)16(21-17)12-7-5-4-6-8-12/h4-11,17H,1-3H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = PXBVEXGRHZFEOF-UHFFFAOYSA-N
}}
'''Camazepam'''<ref>DE Patent 2142181</ref> is a [[benzodiazepine]] psychoactive drug, marketed under the brand names '''Albego''', '''Limpidon''' and '''Paxor'''. It is the dimethyl [[carbamate]] [[ester]] of [[temazepam]], a metabolite of [[diazepam]].<ref>{{cite journal |last1=Tammaro |first1=A |last2=Picceo |last3=Gemmellaro |last4=Bonaccorso |year=1977 |title=Camazepam versus placebo. A double-blind clinical study on geriatric patients suffering from psychic complaints. Short Communication |journal=[[Arzneimittel-Forschung]] |volume=27 |issue=11 |pages=2177–8 |pmid=23793 |doi= |first2=MT |first3=P |first4=O}}</ref> While it possesses [[anxiolytic]], [[anticonvulsant]], [[skeletal muscle relaxant]] and [[hypnotic]] properties<ref>{{cite journal |last1=Lu |first1=XL |last2=Yang |year=1994 |title=Enantiomer resolution of camazepam and its derivatives and enantioselective metabolism of camazepam by human liver microsomes. |journal= [[Journal of Chromatography A]] |volume=666 |issue=1–2 |pages=249–57 |pmid=7911374 |doi=10.1016/0021-9673(94)80387-0 |first2=SK}}</ref> it differs from other benzodiazepines in that its [[anxiolytic]] properties are particularly prominent but has comparatively limited [[anticonvulsant]], [[hypnotic]] and [[skeletal muscle relaxant]] properties.

== Pharmacology ==
Camazepam, like others benzodiazepines, produce a variety of therapeutic and adverse effects by binding to the benzodiazepine receptor site on the [[Gaba a receptor|GABA<sub>A</sub> receptor]] and modulating the function of the [[GABA receptor]], the most prolific inhibitory receptor within the [[brain]]. The GABA chemical and receptor system mediates inhibitory or calming effects of camazepam on the nervous system.
Compared to other benzodiazepines, it has reduced side effects such as impaired cognition, reaction times and coordination.<ref>{{cite journal |last1=De Sarro |first1=G |last2=Chimirri |last3=Zappala |last4=Guisti |last5=Lipartiti |last6=De Sarro  |year=1996 |title=Azirino1, 2-d1, 4benzodiazepine derivatives and related 1,4-benzodiazepines as anticonvulsant agents in DBA/2 mice |journal=[[General Pharmacology]] |volume=27 |issue=7 |pages=1155–62 |pmid=8981061 |doi=10.1016/S0306-3623(96)00049-3 |first2=A |first3=M |first4=P |first5=M |first6=A}}</ref><ref>{{cite journal |last1=De Sarro |first1=G |last2=Gitto |last3=Rizzo |last4=Zappia |last5=De Sarro |year=1996 |title=1,4-Benzodiazepine derivatives as anticonvulsant agents in DBA/2 mice |journal=[[General Pharmacology]] |volume=27 |issue=6 |pages=935–41 |pmid=8909973 |first2=R |first3=M |first4=M |first5=A |doi=10.1016/0306-3623(95)02147-7}}</ref><ref>{{cite journal |last1=De Sarro |first1=G |last2=Chimirri |last3=Mckernan |last4=Quirk |last5=Giusti |last6=De Sarro |year=1997 |title=Anticonvulsant activity of azirino1,2-d1,4benzodiazepines and related 1,4-benzodiazepines in mice |journal=[[Pharmacology, Biochemistry, and Behavior]]
 |volume=58 |issue=1 |pages=281–9 |pmid=9264104 |doi=10.1016/S0091-3057(96)00565-5 |first2=A |first3=R |first4=K |first5=P |first6=A}}</ref><ref>{{cite journal |last1=Guthy |first1=H |year=1975 |title=The medicinal treatment of anxiety in alcoholism in the withdrawal stage (author's transl) |journal=[[Munchener Medizinische Wochenschrift]] |volume=117 |issue=35 |pages=1387–90 |pmid=241014 |doi=}}</ref><ref>{{cite journal |last1=Tallone |first1=G |last2=Ghirardi |last3=Bianchi |last4=Ravaccia |last5=Bruni |last6=Loreti |year=1980 |title=Reaction time to acoustic or visual stimuli after administration of camazepam and diazepam in man |journal=[[Arzneimittel-Forschung]] |volume=30 |issue=6 |pages=1021–4 |pmid=6106497 |first2=P |first3=MC |first4=F |first5=G |first6=P}}</ref> which makes it best suited as an anxiolytic because of these reduced sides effects.
Animal studies have shown camazepam and its [[active metabolites]] possess [[anticonvulsant]] properties.<ref>{{cite journal |last1=Morino |first1=A |last2=Sasaki |last3=Mukai |last4=Sugiyama |year=1986 |title=Receptor-mediated model relating anticonvulsant effect to brain levels of camazepam in the presence of its active metabolites |journal=[[Journal of Pharmacokinetics and Biopharmaceutics]] |volume=14 |issue=3 |pages=309–21 |pmid=2878071 |doi=10.1007/BF01106709 |first2=H |first3=H |first4=M}}</ref>
Unlike other benzodiazepines it does not disrupt normal sleep patterns.<ref>{{cite journal |last1=Ferrillo |first1=F |last2=Balestra |last3=Carta |last4=Nuvoli |last5=Pintus |last6=Rosadini |year=1984 |title=Comparison between the central effects of camazepam and temazepam. Computerized analysis of sleep recordings
 |volume=11 |issue=1 |pages=72–6 |journal=[[Neuropsychobiology]] |pmid=6146112 |doi=10.1159/000118055 |first2=V |first3=F |first4=G |first5=C |first6=G}}</ref> Camazepam has been shown in animal experiments to have a very low affinity for [[benzodiazepine receptors]] compared to other benzodiazepines.<ref>{{cite journal |last1=Shibuya |first1=T |last2=Field |last3=Watanabe |last4=Sato |last5=Salafsky |year=1984
 |title=Structure-affinity relationships between several new benzodiazepine derivatives and 3H-diazepam receptor sites |volume=34 |issue=4 |pages=435–40 |journal=[[Japanese Journal of Pharmacology]] |pmid=6144807 |doi=10.1254/jjp.34.435 |first2=R |first3=Y |first4=K |first5=B}}</ref> Compared to temazepam, camazepam has shown roughly equal anxiolytic properties, and less anticonvulsant, sedative and motor-impairing properties.

== Pharmacokinetics ==
Following [[oral administration]], camazepam is almost completely absorbed into the bloodstream, with 90 percent [[bioavailability]] achieved in humans.<ref>{{cite journal |last1=Morino |first1=A |last2=Nakamura |last3=Nakanishi |last4=Tatewaki |last5=Sugiyama |year=1985 |title=Species differences in the disposition and metabolism of camazepam |journal=[[Xenobiotica]] |volume=15 |issue=12 |pages=1033–43 |pmid=2868575 |doi=10.3109/00498258509049098 |first2=A |first3=K |first4=N |first5=M}}</ref> 
In the human camazepam is metabolised into the [[active metabolite]] [[temazepam]].<ref>{{cite journal |last1=Riva |first1=R |last2=Albani |last3=Baruzzi |year=1982 |title=Quantitative determination of camazepam and its metabolite temazepam in man by gas-liquid chromatography with electron-capture detection |volume=37 |issue=1 |pages=15–9 |journal=[[Il Farmaco]]; edizione pratica |pmid=6120096 |first2=F |first3=A}}</ref> Studies in dogs have shown that the half-life of the terminal elimination phase ranged from 6.4 to 10.5 h.<ref name="pmid6127087">{{cite journal |vauthors=Legheand J, Cuisinaud G, Bernard N, Riotte M, Sassard J |title=Pharmacokinetics of intravenous camazepam in dogs |journal=Arzneimittel-Forschung |volume=32 |issue=7 |pages=752–6 |year=1982 |pmid=6127087 |doi= |url= }}<!--|accessdate=2015-01-03--></ref>

== Medical uses ==
Camazepam is indicated for the short-term treatment of [[insomnia]] and [[anxiety]]. As with other benzodiazepines, its use should be reserved for those patients in which the sleep disorder is severe, disabling or causes marked distress.

== Adverse effects ==
With higher doses such as 40&nbsp;mg of camazepam, impairments similar to those caused by other benzodiazepines manifest as disrupted sleep patterns and impaired cognitive performance.<ref>{{cite journal |last1=Nicholson |first1=AN |last2=Stone |year=1982 |title=Hypnotic activity and effects on performance of lormetazepam and camazepam--analogues of temazepam |journal=[[British Journal of Clinical Pharmacology]] |volume=13 |issue=3 |pages=433–9 |pmid=6120717 |pmc=1402107 |first2=BM |doi=10.1111/j.1365-2125.1982.tb01398.x}}</ref>  [[Skin disorders]] have been reported with use of camazepam however.<ref>{{cite journal |last1=Stricker |first1=BH |year=1984 |title=Skin disorders caused by the use of camazepam (Albego) |journal=[[Nederlands tijdschrift voor geneeskunde]] |volume=128 |issue=18 |pages=870–2 |pmid=6145108 |doi=}}</ref> One study has shown that camazepam may increase attention.<ref>{{cite journal |last1=Schmitt |first1=EJ |last2=Rochels |last3=Beck |last4=Mauersberg |year=1980 |title=Visual perception under the influence of a tranquilizer (author's transl) |volume=177 |issue=6 |pages=875–7 |journal=[[Klinische Monatsblätter für Augenheilkunde]]
 |pmid=6110803 |doi=10.1055/s-2008-1057748 |first2=R |first3=D |first4=L}}</ref>

== Contraindications ==
Use of camazepam is contraindicated in subjects with known hypersensitivity to drug or allergy to other drugs in the benzodiazepine class or any excipients contained in the pharmaceutical form.
Use of camazepam should be avoided or carefully monitored by medical professionals in individuals with the following conditions: [[myasthenia gravis]], severe liver deficiencies (e.g., [[cirrhosis]]), severe [[sleep apnea]], pre-existing [[respiratory depression]] or cronic pulmonary insufficiency.

==See also==
*[[Benzodiazepine]]

==References==
{{reflist|30em}}

==External links==
* [http://www.inchem.org/documents/pims/pharm/pim283.htm Inchem - Camazepam]

{{Benzodiazepines}}
{{Anxiolytics}}
{{GABAAR PAMs}}

[[Category:Benzodiazepines]]
[[Category:Hypnotics]]
[[Category:Carbamates]]
[[Category:Lactams]]
[[Category:Chloroarenes]]
[[Category:GABAA receptor positive allosteric modulators]]